Biotech Values

[mcbio]

AMGN—Repatha shows statsig reduction in CV risk (and non-inferior cognitive function relative to placebo)

Do you view this news as positive for ESPR? Assuming it's at least an incremental positive for ultimate outcome of ESPR's P3 CVOT though I think you separately expressed concerns about enrollment for that trial. (BTW ESPR shares are up almost 20% today at time of this post.)